{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-079769","form_type":"8-K","ticker":null,"cik":"0001183765","company_name":"Molecular Templates, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.582138+00:00","generated_at":"2026-06-04T05:47:36.536363+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Molecular Templates announces $9.5M private placement offering, amends second tranche of July 2023 deal","bullets":["Gross proceeds of $9.5M from amended second tranche; issuing 1.21M common shares, 2.46M prefunded warrants, and 7.34M common warrants at combined $2.60 per share and warrant.","Financing led by existing investor BVF Partners with BB Biotech AG and Santé.","Anticipated closing April 2, 2024; net proceeds to fund clinical studies, working capital, and general corporate purposes.","Stifel acting as sole placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-079769","json":"https://secwatch.observer/filing/0001193125-24-079769.json","markdown":"https://secwatch.observer/filing/0001193125-24-079769.md","text":"https://secwatch.observer/filing/0001193125-24-079769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524079769/0001193125-24-079769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524079769/d800096d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:47:36.536363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5d8ddc1e570431448b260d7184ba473dfab6ec6","claim":"Molecular Templates, Inc. amended Amended and Restated Securities Purchase Agreement with certain institutional and accredited investors (the \"Purchasers\") valued at $9.5 million (effective 2024-03-28).","evidence_excerpt":"On March 28, 2024, the Company and certain institutional and accredited investors (the “Purchasers”) entered into an Amended and Restated Securities Purchase Agreement (as amended and restated, the “Securities Purchase Agreement”) pursuant to which the Company will issue securities with an aggregate purchase price of $9.5 million on amended and restated second tranche terms.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524079769/0001193125-24-079769-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors (the \"Purchasers\")"},{"label":"Value","value":"$9.5 million"},{"label":"Effective","value":"2024-03-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}